Persist: Prospective Observational Cohort Study To Assess Persistence Of Inflectra(tm) (Infliximab) In Patients With Rheumatoid Diseases Who Are Either Naive To Biologics Or Switched From Stable Remicade(tm) (Infliximab)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PERSIST
- Sponsors Pfizer
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2017 Status changed from active, no longer recruiting to recruiting.
- 23 May 2017 Planned primary completion date changed from 31 Jul 2018 to 31 Dec 2018.